Furthermore, treatment with TGF-β1 antagonist or inhibitor of TGF-β receptor I diminished the effects of CRC-EVs on cell viability, Smad signaling (Figure 5A) and expression levels of Treg-related genes (Figure 5B) in Jurkat cells. Here, TGFB1 is linked to colorectal carcinoma.